Teaching hospital

UT Health San Antonio doctors among first to implant rechargeable deep brain stimulation device

Retrieved on: 
Thursday, February 15, 2024

SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.

Key Points: 
  • SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.
  • Deep brain stimulation, known as DBS, is the placement of electrodes in the brain connected to a battery-operated generator in the chest similar to a cardiac pacemaker.
  • Note: Neither UT Health San Antonio nor University Health endorses commercial products or services by name.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

Paul Tornetta III, MD, PhD, FAAOS, Named 92nd President of the American Academy of Orthopaedic Surgeons

Retrieved on: 
Wednesday, February 14, 2024

SAN FRANCISCO, Feb. 14, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced Boston orthopaedic trauma surgeon Paul Tornetta III, MD, PhD, FAAOS, as its new president for 2024-2025.

Key Points: 
  • SAN FRANCISCO, Feb. 14, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced Boston orthopaedic trauma surgeon Paul Tornetta III, MD, PhD, FAAOS, as its new president for 2024-2025.
  • In his acceptance speech, Dr. Tornetta said, "I am honored and humbled to serve as AAOS president.
  • As orthopaedic surgeons, we share a strong bond based in helping others.
  • He is past president of the Orthopaedic Trauma Association (OTA) and served on the executive committee of the American Orthopaedic Association (AOA) for more than a decade.

HKS, Perkins&Will, and McCarthy Vaughn Partnership Selected to Collaborate on Pediatric Campus That Will be Among Largest in U.S.

Retrieved on: 
Tuesday, February 13, 2024

The new campus, which will replace the current Children's Health hospital in Dallas, is designed to be one of the largest, most transformative pediatric hospitals in the nation.

Key Points: 
  • The new campus, which will replace the current Children's Health hospital in Dallas, is designed to be one of the largest, most transformative pediatric hospitals in the nation.
  • McCarthy Vaughn Partnership (MVP) – a joint venture of McCarthy Building Companies , Inc. and J.T.
  • Vaughn Construction LLC – will serve as construction manager for the $5 billion project, which will include 552 beds and 4.5 million square feet of construction.
  • Children's Health anticipates beginning construction on the new hospital campus in the second half of 2024.

Children's Health and UT Southwestern Announce Plans for Transformative New Pediatric Campus in Dallas' Southwestern Medical District

Retrieved on: 
Wednesday, February 7, 2024

DALLAS, Feb. 7, 2024 /PRNewswire/ -- Children's HealthSM and UT Southwestern Medical Center unveiled plans for a new $5 billion pediatric health campus in Dallas' Southwestern Medical District today. Spanning more than 33 acres, the new pediatric campus offers a patient-centric design that can meet the rapidly increasing need for more pediatric services from the most common to the most complex. It will serve as a joint hub for innovation, academic research and training, and the development of life-saving technologies to provide exemplary care for the youngest members of our community.

Key Points: 
  • New Multi-tower Hospital to Replace Children's Medical Center Dallas to Meet Surging Demand for Pediatric Care, Research and Training
    DALLAS, Feb. 7, 2024 /PRNewswire/ -- Children's HealthSM and UT Southwestern Medical Center unveiled plans for a new $5 billion pediatric health campus in Dallas' Southwestern Medical District today.
  • Life-changing treatments, pioneering research, and training the next generation of pediatric providers are the hallmarks of the Children's Health and UT Southwestern legacy.
  • The new pediatric campus adds to the ongoing investments Children's Health continues to make to meet the region's growing pediatric medical and surgical needs.
  • In 2025, Children's Health will occupy the second floor of the 150,000-square-foot UT Southwestern Medical Center at RedBird, part of the Reimagine RedBird development.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

North Shore University Hospital completes $560M surgical tower

Retrieved on: 
Thursday, February 1, 2024

Seventy years after North Shore University Hospital (NSUH) first opened its doors, the Level I trauma center and quaternary care teaching hospital today announced the completion of the Petrocelli Surgical Pavilion, a landmark decades-long project that will transform health care in the region.

Key Points: 
  • Seventy years after North Shore University Hospital (NSUH) first opened its doors, the Level I trauma center and quaternary care teaching hospital today announced the completion of the Petrocelli Surgical Pavilion, a landmark decades-long project that will transform health care in the region.
  • View the full release here: https://www.businesswire.com/news/home/20240201960010/en/
    Northwell Health CEO Michael Dowling (with scissors) and Trustee Chair Margaret Crotty (right) surrounded by Northwell leaders and members of the Petrocelli family at the dedication of the $560 million Petrocelli Surgical Pavilion at North Shore University Hospital in Manhasset, NY.
  • In 2023, CMS gave the hospital its highest 5-star rating while US News & World Report named the hospital No.
  • “North Shore University Hospital has made tremendous strides from its roots as a small community hospital.

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030 call for projects, operated on behalf of the French government by Bpifrance, for the "FLASHDEEP" project, for an amount of 38 million euros

Retrieved on: 
Friday, February 2, 2024

FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).

Key Points: 
  • FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).
  • The particle acceleration technology developed by THERYQ stems from research initiated by the European Organization for Nuclear Research (CERN) and the University Hospital of Lausanne (CHUV).
  • The first clinical FLASHDEEP device will be installed in France, at Gustave Roussy, late 2026, to conduct clinical trials with eligible patients.
  • Ultimately, it will lead to the revival of a French radiotherapy industrial sector, a field that has been neglected since the late 1980s.

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

Retrieved on: 
Friday, January 19, 2024

To register for the event, click here .

Key Points: 
  • To register for the event, click here .
  • The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with:
    KOL Marc Ferrer, MD, PhD (Vall d'Hebron University Hospital), PORTICO E.U.
  • KOL Sarah Fineberg, MD, PhD (Yale School of Medicine), a Psychiatrist not involved with PORTICO to provide an independent clinician’s perspective on the potential clinical and real-world implications for the results.
  • A replay of the webcast will be available on the company’s website after the event.

MEDITWIN Brings Together French Science and Technology Excellence Around Virtual Twins for the Future of Medical Care

Retrieved on: 
Wednesday, January 24, 2024

MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.

Key Points: 
  • MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.
  • The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment.
  • Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology.
  • The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare.

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on: 
Wednesday, January 24, 2024

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points: 
  • Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
  • It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
  • The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
  • The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."